New Listing News | Balitien Hong Kong IPO approved by China Securities Regulatory Commission

On December 12th, the China Securities Regulatory Commission issued a notice regarding the overseas issuance and listing filing of Sichuan Bioli Tianheng Pharmaceutical Co., Ltd. The company plans to issue no more than 24.271 million shares of overseas listed common stock and list on the Hong Kong Stock Exchange. According to the prospectus, Bioli Tianheng established SystImmune in Seattle, United States ten years ago in 2014, and began developing the first-in-class EGFR HER3 bispecific ADC (BL-B01D1). Ten years later, the company reached a total value of 8.4 billion US dollars, with an initial payment of 800 million US dollars, making it the largest global strategic licensing and cooperation transaction in the global ADC field for a single asset to date with BMS for BL-B01D1. The company strives to achieve breakthrough therapeutic effects through breakthrough innovations, bringing more survival opportunities to every cancer patient worldwide. After ten years of efforts, the company has built: 1) a globally leading innovative ADC drug development platform, successfully developing a pipeline of 6 innovative ADC drugs, including BL-B01D1, which have entered clinical stages, and conducting approximately 60 clinical studies, including 9 late-stage III clinical trials and 13 first-line II clinical trials; 2) a globally leading innovative multi-specific antibody drug development platform, successfully developing a pipeline of 4 GNC innovative multi-specific antibody drugs, including GNC-077, which have entered IND or clinical stages, and conducting 10 clinical studies.